Literature DB >> 9420288

Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.

R M Diaz1, T Eisen, I R Hart, R G Vile.   

Abstract

To generate transcriptionally targeted vectors, tissue-specific elements of the human tyrosinase promoter were exchanged with corresponding viral elements in the Moloney murine leukemia virus long terminal repeat (LTR). From these experiments, a vesicular stomatitis virus type G pseudotyped, hybrid LTR vector that contained three tyrosinase enhancer elements and gave high-level, tightly tissue-specific expression at high titers (3 x 10(7) CFU/ml) was constructed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420288      PMCID: PMC109437     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Identification of a cis-acting element that enhances the pigment cell-specific expression of the human tyrosinase gene.

Authors:  K Shibata; Y Muraosa; Y Tomita; H Tagami; S Shibahara
Journal:  J Biol Chem       Date:  1992-10-15       Impact factor: 5.157

2.  Tissue selectivity of murine leukemia virus infection is determined by long terminal repeat sequences.

Authors:  C A Rosen; W A Haseltine; J Lenz; R Ruprecht; M W Cloyd
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

3.  Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats.

Authors:  M K Short; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

4.  Construction and use of a safe and efficient amphotropic packaging cell line.

Authors:  D Markowitz; S Goff; A Bank
Journal:  Virology       Date:  1988-12       Impact factor: 3.616

5.  Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism.

Authors:  M Emerman; H M Temin
Journal:  Cell       Date:  1984-12       Impact factor: 41.582

6.  Substitution of murine transthyretin (prealbumin) regulatory sequences into the Moloney murine leukemia virus long terminal repeat yields infectious virus with altered biological properties.

Authors:  G Feuer; H Fan
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element.

Authors:  A L Boral; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

8.  Negative control region at the 5' end of murine leukemia virus long terminal repeats.

Authors:  J R Flanagan; A M Krieg; E E Max; A S Khan
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

9.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

Authors:  T D Palmer; G J Rosman; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

10.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells.

Authors:  S F Yu; T von Rüden; P W Kantoff; C Garber; M Seiberg; U Rüther; W F Anderson; E F Wagner; E Gilboa
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

View more
  14 in total

1.  Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements.

Authors:  Juraj Hlavaty; Anika Stracke; Dieter Klein; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 2.  Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.

Authors:  Ethlinn V B van Gaal; Wim E Hennink; Daan J A Crommelin; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

3.  Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.

Authors:  Christian Metzl; Daniela Mischek; Brian Salmons; Walter H Günzburg; Matthias Renner; Daniel Portsmouth
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector.

Authors:  Kei Hiraoka; Takahiro Kimura; Christopher R Logg; Noriyuki Kasahara
Journal:  Clin Cancer Res       Date:  2006-12-01       Impact factor: 12.531

5.  Tissue-specific transcriptional targeting of a replication-competent retroviral vector.

Authors:  Christopher R Logg; Aki Logg; Robert J Matusik; Bernard H Bochner; Noriyuki Kasahara
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences.

Authors:  U Jäger; Y Zhao; C D Porter
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Tumor-specific suicide gene therapy for hepatocellular carcinoma by transcriptionally targeted retroviral replicating vectors.

Authors:  Y-H Lai; C-C Lin; S-H Chen; C-K Tai
Journal:  Gene Ther       Date:  2014-10-30       Impact factor: 5.250

8.  A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors.

Authors:  C R Logg; C K Tai; A Logg; W F Anderson; N Kasahara
Journal:  Hum Gene Ther       Date:  2001-05-20       Impact factor: 5.695

9.  Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.

Authors:  Robert White; Nicole Chenciner; Gregory Bonello; Mary Salas; Philippe Blancou; Marie-Claire Gauduin
Journal:  Vaccine       Date:  2013-11-25       Impact factor: 3.641

10.  Promoters with cancer cell-specific activity for melanoma gene therapy.

Authors:  V V Pleshkan; I V Alekseenko; M V Zinovyeva; T V Vinogradova; E D Sverdlov
Journal:  Acta Naturae       Date:  2011-04       Impact factor: 1.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.